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RESUMEN
Nuevos avances sobre el efecto de las lipoproteínas
en la aterosclerosis: Una aproximación nutrigenómica.
La aterosclerosis es una enfermedad en la que múltiples
factores, entre los que se encuentra la dieta, contribuyen a
la degradación de la pared vascular. En la etiología de la ate-
rogénesis son determinantes las lipoproteínas plasmá-
ticas y los distintos tipos celulares de la pared vascular, 
incluyendo una respuesta inflamatoria. La ingesta de ali-
mentos afecta la concentración y composición de las lipopro-
teínas, ejerciendo un papel de riesgo o protector durante las
diferentes etapas del proceso aterosclerótico. Es importante
destacar que la naturaleza de las lipoproteínas y por lo tan-
to su papel en la enfermedad cardiovascular, también de-
pende del tiempo transcurrido entre comidas. Por ejemplo,
las lipoproteínas postprandiales ricas en triglicéridos, es 
decir aquellas que se originan inmediatamente después de
la ingestión de una comida rica en grasas, poseen una gran
influencia en la aterogénesis que hasta ahora solo se con-
cedía a las lipoproteínas de baja densidad y en ayunas. Los
recientes avances en tecnologías «ómicas» están ayudando
a descifrar los complejos mecanismos celulares y molecula-
res de las lesiones ateroscleróticas originados en las distin-
tas fases de la alimentación. En esta revisión se discuten los
nuevos avances en la investigación sobre los efectos vascu-
lares de lipoproteínas plasmáticas en estado de ayuno y
postprandial, resaltando aquellos obtenidos con la tecnolo-
gía de la nutrigenómica.
PALABRAS CLAVE: Aterosclerosis – Células vasculares
– Dieta – Lipoproteínas – Periodo postprandial.
SUMMARY
Recent advances in lipoprotein and atherosclerosis:
A nutrigenomic approach.
Atherosclerosis is a disease in which multiple factors
contribute to the degeneration of the vascular wall. Many risk
factors have been identified as having influence on the
progression of atherosclerosis among them, the type of diet.
Multifactorial interaction among lipoproteins, vascular wall
cells, and inflammatory mediators has been recognised as the
basis of atherogenesis. Dietary intake affects lipoprotein
concentration and composition providing risk or protection at
several stages of atherosclerosis. More intriguingly, it has 
been demonstrated that the extent to which each lipid or
lipoprotein is associated with cardiovascular disease depends
on the time to last meal; thus, postprandial lipoproteins, main
lipoproteins in blood after a high-fat meal, have been shown 
to strongly influence atherogenesis. As a complex biological
process, the full cellular and molecular characterization of
atherosclerosis derived by diet, calls for application of the
newly developing “omics” techniques of analysis. This review
will considered recent studies using high-throughput
technologies and a nutrigenomic approach to reveal the
patho-physiological effects that the fasting and postprandial
lipoproteins may exert on the vascular wall.
KEY-WORDS: Atherosclerosis – Diet – Lipoproteins –
Nutrigenomics – Postprandial state – Vascular cells.
1. INTRODUCTION
Since the human genoma DNA sequence was
completed, nutrition research has undergone a shift
from epidemiology to molecular biology and
genetics. In that sense, the relationships between
nutrient availability and adaptive changes in gene
expression are critical to understanding the role
of nutrition in health and disease. Unbalanced
diets alter nutrient-gene interaction increasing
the development of chronic disease. Nutrient 
modulation of gene expression serves to protect the
cell from the deleterious effects of both under-
nutrition and over-nutrition. It is now well
established that modifying the consumption of
certain dietary compounds can prevent some
monogenic diseases (a single dysfunctional gene is
responsible for disease), such as galactosemia and
phenylketonuria (van Spronsen et al., 2001;
Thompson et al., 2003). In contrast, dietary
interventions to prevent the onset of polygenic 
diseases such as cardiovascular disease (CVD),
cancer, diabetes type II and obesity requires not
only knowledge of how a single nutrient may affect
a biological system but also how a mixture of
nutrients will interact to modulate biological
functions (Arab, 2004).
Atherosclerosis is a complex, multifactorial
disease associated with accumulation of lipids in 
lesions along blood vessels, leading to the
occlusion of blood flow, with oxidative and
inflammatory components playing major roles in
its cause. Environmental factors with particular
emphasis on nutrition as well genetic factors
appear to be responsible for these aberrant
oxidative and inflammatory components and the
lipid abnormalities associated with the disease.
Diet may contribute to the atherosclerotic process
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by affecting lipoprotein concentration, their 
composition (Abia et al., 2001; Furtado et al., 2008)
and degree of oxidation (Fitó et al., 2007). Much of
the knowledge about the relationship between
lipoprotein metabolism and the development of
atherosclerosis is based on analysis in the fasting 
state reflecting endogenous metabolism,
particularly; the focus has been on the role of
low-density lipoprotein (LDL), and of oxidatively
modified LDL (oxLDL) in the initiation and
progression of this disease. Although the presence
of oxLDL, in general, supports the oxidative
hypothesis of atherogenesis, accumulating 
evidence indicates that it is mainly specific oxidized
phospholipids on apoB-100 particles, and 
particularly on the Lp(a) fraction, that correlate with
increased CVD risk (Tsimikas et al., 2006).
Contrary to LDL, high-density lipoprotein (HDL) has
several beneficial protective properties (Tall, 2008);
however, remodelling of HDL due to 
chemical/physical modifications can dramatically
affect its functions, leading to dysfunctional HDL
that could promote atherogenesis (Hurtado et al.,
1996, Valiyaveettil et al., 2008).
Over the years, univariate analyses have
implicated triglycerides as a contributor of
atherosclerosis. In two recent prospective studies,
non-fasting plasma triglyceride levels have 
represented an independent cardiovascular risk
factor to a greater extent than fasting levels
(Bansal et al., 2007; Nordestgaard et al., 2007).
Furthermore, a recent study (Mora et al., 2008) has
demonstrated that HDL cholesterol, triglycerides,
total/HDL cholesterol ratio, and apolipoprotein A-1
predict CVD when measured in the non-fasting
state. This is in line with the fact that Western
population spend most of the day in the
postprandial state. Postprandial lipemia is
characterized by a rise of triglyceride-rich
lipoproteins (TRL) [chylomicrons, very-low density
lipoproteins (VLDL) and their respective remnant
particles] and small dense LDL particles after a rich
fat meal. Postprandial lipid and lipoprotein
metabolism is modulated by meal composition,
several lifestyle conditions, physiological factors
and pathological conditions (Lopez-Miranda et al.,
2007). Remodelling of lipoproteins in this stage
greatly out-number those occurring at fasting
conditions, being food intake the main mechanism
inducing these alterations. The magnitude of
postprandial lipemia represents an important risk
factor for the development of atherosclerosis and
coronary artery disease (Cohn, 2006), it is therefore
becoming increasingly evident that future efforts to
study atherosclerosis should include the effects of
postprandial lipoproteins.
Although certain key risk factors affecting
atherosclerosis have been identified, the full
molecular characterization will remain a challenge
in the next century to come. As a complex biological
process, the cellular and molecular details of the
growth, progression and regression of the vascular
lesions of atherosclerosis call for application of the
newly developing “omics” techniques of analysis.
Nutrigenomics is a study of interactions of dietary
components with the genoma and the resulting
changes in gene expression, structure, and function
of proteins and other metabolites (Subbiah, 2008).
Profiling gene expression using microarrays has
proven useful in identifying new genes that may
contribute to features of the atherosclerosis lesion
(transcriptomics). Because a change in gene
expression does not necessarily lead to
measurable changes in plasma protein levels,
profiling proteoma rather than mRNA, has became
and complementary technique (proteomics). This
review summarizes more recent studies, including
these technologies, that have lead to the
development of new hypothesis concerning the
cellular response to lipoproteins and to identify the
major cellular pathways responsive to them.
Furthermore, we present data that support the role
of TRL in the atherosclerosis process.
2. FASTING LIPOPROTEIN CONTROL 
OF GENE AND PROTEIN EXPRESSION 
IN ATHEROSCLEROSIS
LDL cholesterol is considered a major factor in
atherosclerosis development. An increase in plasma
LDL levels leads to an increase of entry of LDL into
the intima of susceptible arteries. Depending on the
degree of oxidation, oxLDL have been proposed to be
involved in many atherogenic changes in the vascular
wall such as, proliferation, migration, apoptosis and
necrosis of vascular cells, furthermore, oxLDL itself
induces oxidative stress in endothelial cells (EC),
smooth muscle cells (SMC), and macrophages,
resulting in atherogenic plaque formation (Galle et al.,
2006). During an early stage of atherosclerosis,
oxLDL is incorporated into macrophages via
receptor-mediated endocytosis, leading to
macrophage transformation into foam cells and thus
the plaque formation of atherosclerotic lesions. As the
lesion progresses, a necrotic core of lipid, oxidised
lipids, and other cell debris accumulates. Increases in
extracellular matrix production results in the
formation of a fibrous cap or plaque that walls off
the necrotic core from the endothelium. In time,
increased lesion size and local proliferation of SMC
can cause to protrude into the lumen. Weakening
events can lead to plaque rupture, thrombosis, and
myocardial infarction or stroke.
2.1. Effect of lipoproteins on regulation 
of gene and protein expression 
in vascular endothelial cells
It has been proposed that the biological effect of
modified lipoproteins may be partly attributed to its
effect on a shift of the pattern of gene expression in
endothelial cells. Thus, the analysis of differential
gene expression in the endothelium is critical to our
understanding of the sequence of events leading to
the formation of atherosclerotic lesion. This approach
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has been utilised by Virgili et al. (2003), to identify
genes involved in atherogenesis in primary human
umbilical vein endothelial cells (HUVEC) challenged
with oxLDL. Treatment of HUVEC with oxLDL altered
the expression of genes encoding for transcription
factors (Gata binding protein 2, GATA-2; sterol
regulatory element-binding protein 1, SREBP1 and
SREBP2), cell receptors (Tromboxane A2 receptor,
TXA2R), adhesion molecules (vinculin, cell-surface
glycoprotein MUC18), extracellular matrix proteins
(matrix metalloproteinase 2, MMP2; MMP9), and
enzymes involved in cholesterol metabolism that
compose a “response to injury” type of effect. OxLDL
could induce alterations in the signalling pathways
mediated by platelet derived factor receptor (PDGFR)
and farnesyl transferase (FTase), which could in turn
lead to metabolic dysfunction in the endothelium.
Phospholipid oxidation products of 1-palmitoyl-2-
arachidodonyl-sn-glycero-3-phosphorylcholine
(PAPC) present in midly oxLDL activate EC leading
to enhance monocyte/EC interaction (Berliner et al.,
2001). Oxidised phospholipids in human plasma
associated with apo(a) have shown to be predictive
of the presence and progression of atherosclerosis
(Tsimikas et al., 2005). Genes and global pathways
involved in the inflammatory effects of oxPAP have
been described by Gargalovic et al. (2006), by
examining human aortic EC (HAEC) cultures
derived from multiple heart transplant donors. The
approach was based on the fact that a natural
population will exhibit multiple genetic or epigenetic
variations that perturb the expression of individual
genes, as well as entire pathways. These variations
could be quantitated by expression array profiling
and analysed by using system biology approaches.
Expression arrays yielded 1,043 differentially
expressed genes, some of these genes including
interleukin 8 (IL-8), heme oxygenase 1 (HMOX1)
and members of the SREBP pathway, have
previously been shown to be regulated by oxPAPC,
but the majority represented novel oxPAPC targets
(see Gargalovic et al., 2006 for more detail). A
particularly important finding of the study was that
HAEC exposure to oxidised lipids results in the
induction of the unfolded protein response
(UPR), which directly participates in modulating
inflammatory response. UPR, and more specifically
the activating transcription factor 4 (ATF4), was an
important mediator of IL-8 expression in HAEC.
Recent studies have demonstrated that HDL
treatment of HAEC downregulates the inflammatory
and pro-oxidant effects of ox-PAPC. HDL has a
protective role in regulating ox-PAPC signalling by
reducing the induction of chemotactic, sterol
biosynthetic and UPR genes, and reducing ox-
PAPC-induced chemotactic activity and monocyte
binding regulated by IL-8 and monocyte chemotactic
protein 1 (MCP-1) (Gharavi et al., 2007).
Proteomic studies have been proved to be a
useful tool with which to understand the extensive
mechanisms underlying atherosclerosis. Kinumi et
al. (2005) showed that oxLDL-stimulated HUVEC
resulted in the suppression of cell proliferation,
which was ascribed to protein modifications, such
as phosphorylation and autodegradation, and/or
altered expression of nucleophosmin, stathmin, and
nucleolin under these oxidative stress conditions.
Furthermore, different forms of oxidatively modified
LDL regulated HUVEC protein expression in
different patterns (Chen et al., 2007), LDL isolated
from familial hypercholesterolemia subjects (FH-
LDL) expressed approximately 3-fold higher
concentration of MCP-1 than did cells subject to
copper-oxidized LDL and atheroma-derived LDL (a-
LDL). The expression of heterogeneous nuclear
ribonucleoprotein (hnRNP) C1/C2 was enhanced
by FH-LDL and a-LDL, while glutation transferase
was enhanced only by FH-LDL. This study suggests 
different roles for different oxLDL forms in inducing
atherosclerosis.
2.2. Effect of lipoproteins on regulation 
of gene and protein expression 
in vascular smooth muscle cells
OxLDL induce a wide range of biological effects
on SMC. The response of cultured SMC depends on
the degree of oxidation and the extracellular
concentration of oxLDL (Kita et al., 2001). Global 
analysis of gene expression profiling in oxLDL treated
aortic SMC (HASMC), demonstrated that oxLDL
predominantly elevates expression of genes involved
in cell-cell interactions, membrane transport, 
oncogenesis, apoptosis and transcription as well as
down regulation of genes responsible for protein,
nuclei acid biosynthesis, lipid metabolism and 
humoral responses. Two transcripts for metastasis-
related protein (MB2) and scavenger receptor SREC-
II were firstly identified in vascular SMC (Sukhanov et
al., 2003). To evaluate the global effects of oxLDL on
cellular groups of proteins and to compared protein
microarray data with the cDNA microarray-base gene
expression results, Sukhanov and Delafontaine
(2005) used protein chip-based microarray
technology.This technique is based on highly specific
interactions between a set of nonlabeled antibodies
spotted on the activated side (biochip) and a mix of
labelled antibodies taken from experimental and
control sample (probe). Results revealed the major
pattern of oxLDL-induced effects on HASMC
functions, proteins involved in cell-cell interaction were
predominantly up-regulated by ox-LDL (cadherin-3,
cadhrin-5 and integrin 5), whereas those involved 
in nucleic acid and protein biosynthesis 
(tRNA-synthetases, phosphoribosyltransferase, 
deoxyxytidine kinase) and in cellular structure and
humoral response were underexpressed in oxLDL-
treated HASMC.
OxLDL also differentially expressed genes
involved in redox homeostasis, Ca2+ signalling,
immune response and apoptosis in coronary artery
SMC (Reeve et al., 2007). oxLDL induced the
expression of glutathione reductase, NAD(P)H
dehydrogenase-1, calcium/calmodulin-dependent
protein kinase kinase 2 (CAMKK2), heat shock
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factor-1 (HSF-1) and reduced the mRNA levels of
vascular endothelial growth factor A (VEGFA)
precursor and apoptosis inhibitor 5 (API5), among
others. OxLDL induced an oxidative stress
response in those cells, as indicated by additional
promoted expression of manganese superoxide
dismutase (MnSOD), hemoxygenase-1 (HO-1) and
ferritine, which was not accompanied by activation
of the unfolded protein response. The high levels of
oxidative estress induced by oxLDL caused
caspase-indepented coronary arteries SMC death.
Padró et al. (2008) have recently identified
using a quantitative proteomic approach (two-
dimensional gel electrophoresis coupled with mass
spectrometry) that native and aggregated LDL
induce significant changes in proteins directly
involved in the assembly/disassembly and 
stabilization of human coronary SMC (HCSMC)
cytoskeleton network. LDL both in their native form
or modified by aggregation, alter the expression
and proteomic pattern of different isoforms of
myosin regulatory light chain, which regulation of
phosphorilation is proposed to play an important
role in controlling morphological changes during
cell attachment, spreading and migration.
2.3. Effect of lipoproteins on regulation 
of gene and protein expression 
in macrophages
Monocyte-derived macrophages play a crucial
role in the pathogenesis of atherosclerosis. In the
early stages of the atherosclerosis lesion (fatty
streak), lipid-laden macrophages (foam cells) 
appear to be most prominent. Several studies have
used a proteomic approach to identify the response
to human monoblastic leukaemia (U937) cell line
(Yu et al., 2003, Yang et al., 2007), THP-1 cells
(Fach et al., 2004) and human monocyte-derived
macrophages (Dupont et al., 2008) after treatment
with oxLDL. Among the intracellular and secreted
proteins that were found to be modulated by oxLDL,
several were involved in atherosclerosis including
heat shock proteins (HSP), proteins involved in
oxidative stress (catalase, aconitase and pyruvate
kinase) and proteins involved in cytoskeletal
stabilization, such as F-actin capping proteins 
involved in Actin polymerization and motility
(gelsolin, CapG and CapZ) and vimentin.
OxLDL have been suggested to modulate gene
expression in THP-1. Changes in genes that code
for potent intracellular and extracellular signalling
molecules such as the nuclear factor kappa-b (NF-
kB), A20 and numerous cytokines (interleukin 1-
beta, IL-1 and tumor necrosis factor-alpha, TNF-)
and chemokines (macrophage inflammatory protein
1-alpha, Mip-1; Mip-3; Mip-1 and IL-8) were
detected. Furthermore, some of the effects appear
to be mediated through altered regulation of NF-kB
signalling and activation of the nuclear receptors
retinoid X receptor (RXR) and peroxisomal 
proliferators activated receptor (PPAR) (Mikita et
a., 2001). Levula et al. (2006), investigated the
changes in gene expression induced by oxLDL
and oxHDL in healthy human macrophages. Both
lipoproteins seemed to have different, even
contrasting, effects on the gene expression of
macrophage derived foam cells, probably due to 
their different composition or possibly they use
different scavenger receptor to enter these cells.
They suggested new candidate genes for foam cell
formation such as those involved in lipid metabolism
(fatty acid binding protein 3, FABP3; LDL-receptor
protein 1; LRPAP1 and very long chainacyl-coA
dehydrogenase, VLCAD); and in inflammation,
growth and haemostasis (small inducible cytokine
A1, SCYA1; vascular endothelial growth factor 165
receptor 2, VEGF165R2; and thrombospondin 2,
THBS2).
Recent reported findings indicate that there is an
important immunological and inflammatory aspect
of atherosclerosis. Several autoimmune diseases
are associated with accelerated atherosclerosis,
increased plasma levels of circulating oxLDL, anti-
oxLDL antibodies, dyslipidemia and enhance
inflammation (Frostegård, 2005). OxLDL is
immunogenic and elicits the production of 
antibodies, predominantly of the pro-inflammatory
IgG1 and IgG3 isotypes (Saad et al., 2006).
Antibodies from circulating immune complexes
containing oxLDL (oxLDL-IC) activate both 
cell-mediated and humoral immune responses,
both responses are pro-inflammatory and play
an important role in the perpetuation of the
chronic inflammatory reaction characteristic of
atherosclerosis. Recently, gene expression
changes induced by oxLDL-IC have been 
investigated in the human monocytic cell line U937
(Hammad et al., 2008). These studies have shown
early transcriptional responses elicited by oxLDL-IC
that may underlie its cytoprotective and
proinflammatory effects compared to oxLDL.
OxLDL-IC uniquely affected the expression of
genes involved; with pro-survival (RAD54B; run and
five domains-containing protein 3, RUFY3; small
nuclear ribonucleoprotein polypeptide b-double
prime, SNRPB2 and ZBTB24); with stress
response, including UPR which impacts cell
survival; with regulation of transcription; with
endocytosis and intracellular transport of protein
and lipid; with inflammatory responses including
regulation of I-kB/NF-kB cascade and with cytokine
activity. Cross-linking of Fc receptors appears to
be the trigger for most of the transcriptional
responses to oxLDL-IC.
3. NOVEL ATHEROGENIC MECHANISMS
INVOLVED IN POSTPRANDIAL TRL:
MOLECULAR MECHANISMS AND GENE
EXPRESSION STUDIES
Overproduction of TRL, characteristic of
postprandial lipemia leads to a complex series of
events potentially inducing atherogenesis, however,
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the mechanisms by which TRL exert their effect on
the vascular wall are largely unknown.
3.1. Postprandial lipoproteins and endothelial
dysfunction
Remnant like-lipoproteins have been associated
with endothelial dysfunction and coronary artery
disease in subjects with metabolic syndrome
(Nakamura et al., 2005). A large number of genes
are regulated after exposure of endothelial cells to
TRL with the net effect reflecting receptor and non-
receptor mediated pathways that are activated or
inhibited depending on the fatty acid type, lipid and
apolipoprotein composition of TRL and the
presence or absence of lipoprotein lipase (Williams
et al., 2004). TRL have been shown to induce
pro- and anti-inflammatory responses in the 
endothelium, the composition of TRL has been
shown to play a key role in determining these
responses. In that sense, TRL isolated after a meal
enriched in saturated fatty acids induced E-selectin,
vascular cell adhesion molecule 1 (VCAM1) and
lectin-like oxidised-LDL receptor 1 (LOX1) gene
expression to a higher extent when compared to
TRL isolated after a meal enriched in mono and
poly-saturated fatty acids (Williams et al., 2004);
similarly, chylomicrons separated after ingestion of
safflower oil, rich in polyunsaturated linoleic acid,
induced higher adhesion molecule expression
compared with chylomicrons separated after
ingestion of olive oil, rich in monounsaturated oleic
acid (Jagla and Schrezenmeir, 2001). Effects of
lipoproteins on vasoactive substances seem to be
implicated in endothelial dysfunction too. The
endothelium-derived relaxing factor nitric oxide
(NO) has gained increasingly attention as is
regarded as protective against hypertension and
atherosclerosis. In general, high-fat meals have
often been associated with a loss of postprandial 
vascular reactivity compared to low fat meals.
However several studies have shown that
differences in food components and fatty acid
content of the meals may contribute to the effects
observed on vascular reactivity by means of
postprandial lipoproteins modifications. Thus,
meals containing monounsaturated fatty acids +
eicosapentaenoic/docosahexaenoic acids
(EPA/DHA) are able to attenuate the impairment
of endothelial function probably by reducing the
most atherogenic postprandial lipoprotein
subclass containing apolipoproteins B and C
(Hilpert et al., 2007); likewise, consumption of a
saturated fat reduces the anti-inflammatory
potential of postprandial HDL and impairs arterial
endothelial function, meanwhile, the anti-
inflammatory activity of HDL improves after
consumption of polyunsaturated fat (Nicholls et
al., 2006). TRL composition may also contribute
to the changes observed in vascular dysfunction,
thus, TRL isolated after a fish oil meal improves
vascular reactivity, increasing endothelial nitric
oxide synthase (eNOS) and decreasing NADP
oxidase gene expression (Armah et al., 2008).
Postprandial TRL from hypertrigliceridemic
patients but not by normolipidemic subjects
induced a large set of pro-inflammatory (VCAM-1;
endothelial leukocyte adhesion molecule 1, ELAM1;
platelet-endothelial cell adhesion molecule 1,
PECAM1 and IL6) and pro-thrombotic (plasminogen
activator inhibitor 1, PAI-1; a disintegrin-like and
metalloproteinase with thrombospondin type1,
ADAMTs1) genes in endothelial cells. Furthermore,
TRLs induced MCP-1 expression suggesting that
the activation of the endothelium could support both
adhesion and transmigration of leukocytes (Norata
et al., 2006). As the induction of adhesion molecules
and release of chemokines have been associated
with endothelial dysfunction, it can be proposed that
endothelial activation by TRL may promote
endothelial dysfunction observed after a meal.
Activation of the extracellular-signal regulated 
kinase (ERK)1/2 and p38 mitogen-activated protein
kinase (MAPK) pathways and of the transcription
factors cAMP response element-binding protein
(CREB); NF-kB and nuclear factor of activated T
cells (NFAT) (Norata et al., 2003; Norata el al., 2006,
Norata et al., 2007) could be responsible for these
effects. Recently, it has been shown that,
postprandial hypertriglyceridemia is a leukocyte
activator most likely by direct interaction between
TRL and leukocytes and uptake of meal-derived
fatty acids (Alipour et al., 2008). Therefore, binding
of TRL to the leukocytes, may be one of the first
steps in the process of atherosclerosis in contrast to
the present view that it starts by migration of LDL
and TRL-remnants to the sub-endothelium. These
findings highlight novel mechanisms by which
postprandial lipoproteins may influence key
atherogenic processes.
3.2. Effect of postprandial lipoproteins 
on subendothelial cells 
TRL can penetrate the vessel wall (Rapp et al.,
1994) they are taken up by macrophages and
smooth muscle cells and are detectable as part
of foam cells in vascular lesions (Bravo and
Napolitano, 2007). This may support a potential role
of TRL in the subendothelial space. The direct
effects of remnant lipoproteins on SMC and
macrophages and the mechanisms involved have
been reviewed by Kawakami and Yoshida (2005).
Vascular smooth muscle cells migration and
subsequent proliferation from media to intima play
key roles in atherogenesis. Remnant TRLs have
been shown to induce the proliferation (Kawakami
et al., 2003) and migration (Aramaki et al., 2008) of
SMCs via activation of MAPK, in which G
protein–coupled receptor (GPCR)–dependent or
independent protein kinase C (PKC) activation
followed by epidermal growth factor receptor (EGF)
transactivation and heparing-binding EGF-like
growth factor shedding were shown to be involved.
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Aramaki et al. (2008) also showed that LOX-1 acts
as a receptor for remnant TRL in SMC.
The composition of TRL needs to be taken into
account when discussing the effects of TRL on
vascular proliferation (Pacheco et al., 2002). In that
sense, recent cDNA microarray studies (Bermudez
et al., 2008) have shown that isolated human TRL
enriched in monounsaturated (TRL-refined olive
oil; TRL-ROO), saturated (TRL-BUTTER) and 
polyunsaturated fatty acids (TRL-vegetable and fish
oil; TRL-VEFO), can provoke differential gene
expression in human coronary artery smooth
muscle cells. TRL-BUTTER predominantly 
activated genes involved in the regulation of cell
proliferation (cyclin D1, CCND1; Cyclin E1,
CCNE1; retinoblastoma 1, RB1; proliferatinf cells
nuclear antigen, PCNA) and inflammation (IL8;
cyclooxygenase 2, COX2), TRL-VEFO induced the
expression of genes implicated in inflammation
(IL8, IL1B, MCP-1)  while TRL-ROO promoted a
less atherogenic gene profile which could improve
atherosclerotic-plaque stability and support the
prescription of olive oil-enriched diets in secondary
prevention of cardiovascular disease.
4. CONCLUSION
This review summarises recent data that
support the use of “omics” technologies to identify,
in vitro and in vivo studies, a tractable set of new
genes and protein biomarkers candidates of
atherosclerosis that may eventually be developed to
measure the extent, progression, regression and
stability of atherosclerotic lesions provoked by the
diet. While these biomarkers will hopefully develop
into indicative and predictive set of molecules, their
diagnostic power can not be uncoupled from pre-
determined genetic disposition.
The insights gained from the studies of
postprandial lipoproteins may reinforce the
fundamental link between dietary factors and the
aetiology of atherosclerosis.These observations also
suggest that TRL contribute to atherogenesis by
directly affecting the vascular cells. Therefore, future
efforts to study and treat lipids related to
atherogenesis should include postprandial
parameters. Based on the nutrigenomic approache,
we can suggest that the pathophysiological
contribution of postprandial TRL to the development
of atherosclerosis and the stability of the
atherosclerotic plaque could, in part, depend on the 
fatty acid composition of TRL, indicating that 
the quality of the plaque rather than the quantity
may determine the clinical consequences of
atherosclerosis.
Further studies are needed to help to discern
whether the effects of lipoproteins in the fasting and
postprandial state on the genes and proteins
investigated in these studies are relevant under
human physiological conditions. This is not an easy
task, since one major cause for the lack of
nutritionally relevant investigations in humans is the
constraint of being non-invasive when it comes to
sampling for nutritional studies.
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